NEW YORK, Oct. 22, 2018
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE
American: ATNM) announced today that it will host a conference call
and webinar to provide key updates on the advancement of its CD33
program on Friday, October 26, 2018
at 11:00 AM ET. Actinium's CD33
program utilizes the Antibody Radio-Conjugate (ARC),
lintuzumab-Ac-225 for hematologic indications including Acute
Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple
Myeloma (MM). Actinium recently completed its Phase 2 Actimab-A
trial in patients newly diagnosed with AML who are over the age of
60 and unfit for intensive chemotherapy. Dr. Gary Schiller Professor Medicine,
Hematology-Oncology at UCLA Medical Center and Dr. Tapan Kadia, Assistant Professor of Medicine,
Department of Leukemia at the MD Anderson Cancer Center will
highlight Actinium's post Phase 2 trial development plans for
Actimab-A in AML.
Actinium is also developing Actimab-MDS, which is intended to be
a single dose, chemotherapy-sparing targeted conditioning agent for
patients with high-risk MDS. Currently, this patient population
either cannot undergo a bone marrow transplant or have poor
outcomes. Management will provide an update on the regulatory
pathway for Actimab-MDS following positive interactions with the
U.S. Food and Drug Administration (FDA).
Dr. Mark Berger, Actinium's Chief
Medical Officer said, "Our CD33 program has progressed
significantly in 2018 resulting in a highly valuable body of data
that we are using to inform our ongoing development strategy. Our
Antibody Radio-Conjugate approach, given its differentiated
mechanism of action, has allowed us to expand this program beyond a
traditional AML directed approach which is where other CD33
programs in the industry are focused. The unique ability of our
ARC's enable cell killing to occur not just via internalization of
the antigen but also from the cell surface and by crossfire. In
addition, our ARCs labeled with radioactive actinium are
characterized by the high linear energy transfer of alpha radiation
which is able to cause double stranded DNA breaks via a single
alpha particle hit. This potent cell killing power of alpha
radiation when used in an efficiently targeted manner as in our
Actimab program enables us to expand into other radio-sensitive
CD33 expressing malignancies such as multiple myeloma and now for
targeted conditioning for MDS, both of which are indications where
Actinium is developing the only CD33 targeting agent. In addition,
we have moved into a novel combination trial for patients with
significant unmet need with our Actimab-A CLAG-M study. We are
pleased to have made this progress, but we believe the next
evolution of our CD33 program will be even more exciting. As such,
we look forward to highlighting our post Phase 2 trial development
plans for Actimab-A with Dr. Schiller and Dr. Kadia."
Sandesh Seth, Actinium's Chairman
and Chief Executive Officer said, "We are excited to introduce
these latest initiatives as they clearly establish Actinium's
Antibody Radio-Conjugate based CD33 program as the industry leader.
Further, we are about to enter a period that will showcase data
from several of the CD33 program initiatives that this team has
advanced. Given the inherent nature of our technology, the
expertise of our team and strong relationships with thought
leaders, we have been able to craft a development strategy that
leverages the strengths of our drug candidates and Antibody Warhead
Enabling technology platform into indications with high unmet
medical needs. The webinar will showcase the attractiveness of
using our Antibody Radiation-Conjugate approach in meeting these
needs. In addition, it will establish the strategic importance of
Actimab-MDS in enabling our company to develop a multi-asset
pipeline of targeted conditioning agents which have the potential
to improve access and outcomes for patients undergoing bone marrow
transplant and cellular therapy in a chemotherapy-free or
chemotherapy-sparing manner."
Conference call and webcast Participation
Information
Date: Friday,
October 26, 2018
Time: 11:00 AM ET
Webcast Registration:
https://onecast.thinkpragmatic.com/ses/9DnzzB5lR-DnSV3zQJ1LDQ~~
U.S. Participant Dial-in: (718) 865-8336
U.S./Canada Toll Free Dial-in: (855) 427-0225
Conference ID: 4831
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is focused on improving patient
access and outcomes to cellular therapies such as bone marrow
transplant (BMT) and CAR-T with its proprietary, chemotherapy free
or sparing, targeted conditioning technology. Actinium is the only
company with a multi-disease, multi-target, drug development
pipeline focused on targeted conditioning. Its targeted
conditioning technology is enabled by ARC's or Antibody
Radio-Conjugates that combine the targeting ability of monoclonal
antibodies with the cell killing ability of radioisotopes.
Actinium's pipeline of clinical-stage targeted conditioning ARCs
target the antigens CD45 and CD33 for patients with a broad range
of hematologic malignancies including acute myeloid leukemia (AML),
myelodysplastic syndrome (MDS) and multiple myeloma (MM), acute
lymphoblastic leukemia (ALL), Hodgkin's lymphoma and Non-Hodgkin's
lymphoma. Actinium's Iomab-ACT program is designed to be a
universal lymphodepletion technology intended to eliminate the need
for chemotherapy-based conditioning prior to CAR-T or other
adoptive cellular therapies.
Iomab-B, Actinium's lead targeted conditioning product
candidate, is currently enrolling patients in the pivotal Phase 3
SIERRA trial in patients age 55 or older, with active, relapsed or
refractory AML. Iodine-131-apamistamab (Iomab-B), combines the
anti-CD45 monoclonal antibody labeled with iodine-131 for
myeloablation prior to a bone marrow transplant. CD45 is expressed
on leukemia, lymphoma and normal immune cells. Iomab-B has been
studied in over 500 patients in 10 clinical trials in numerous
hematologic diseases. Actinium's Iomab-ACT program is an expansion
of its CD45 program that is intended to be a universal,
chemotherapy-free solution for targeted lymphodepletion prior to
CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is
expected to improve CAR-T cell expansion, reduce CAR-T related
toxicities and expand patient access to CAR-T treatment and
potentially other adoptive cell therapies. Due to its lower payload
dose, lymphodepletion with the Iomab-ACT program can be
accomplished through a single outpatient infusion. Actinium intends
to advance its Iomab-ACT program with CAR-T focused collaborators
from academia and industry.
Actinium's pipeline also includes a potentially best-in-class
CD33 program with its ARC comprised of the anti-CD33 antibody
lintuzumab labeled with the alpha-particle emitter actinium-225.
Its CD33 program is currently being studied in multiple Phase 2 and
Phase 1 clinical trials for targeting conditioning and as a
therapeutic in multiple diseases and indications including AML, MDS
and MM. Actinium applies its CD33 program at high doses to target
CD33+ cells of the myeloid lineage in combination with reduced
intensity conditioning (RIC), which together are intended to result
in myeloablative outcomes with a more benign and well tolerated
profile than high intensity chemotherapy myeloablation. Actinium is
focused on applying its CD33 program at low doses in combination
with other therapeutic modalities including chemotherapy, targeted
agents and immunotherapies.
Actinium is also developing its proprietary AWE or Antibody
Warhead Enabling technology platform which utilizes radioisotopes
including iodine-131 and the highly differentiated actinium-225
coupled with antibodies to target a variety of antigens that are
expressed in hematological and solid tumor cancers. The AWE
technology enables Actinium's internal pipeline and with the
radioisotope Actinium-225 is being utilized in a collaborative
research partnership with Astellas Pharma, Inc. Actinium's clinical
programs and AWE technology platform are covered by a portfolio of
77 patents covering composition of matter, formulations, methods of
use and also methods of manufacturing the radioisotope Actinium-225
in a cyclotron.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals,
Inc.
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Investor Relations
Rx Communications Group
Paula Schwartz
917-322-2216
pschwartz@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-webinar-showcasing-actimab-a-post-phase-2-trial-plans-and-actimab-mds-regulatory-update-300734989.html
SOURCE Actinium Pharmaceuticals, Inc.